Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKOVE-1: Neladalkib in Advanced ALK+ NSCLC and Solid Tumors
NCT05384626Phase 2Recruiting
- Sponsor
- Nuvalent
- Start
- Jun 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label trial of neladalkib in non-small cell lung cancer (NSCLC) and solid tumor (9 arms), sponsored by Nuvalent. Primary endpoints: Dose limiting toxicities at 21 days, Recommended Phase 2 Dose at 21 days and 5 more. Started Jun 2022; status: recruiting.
02
Drugs
neladalkib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05384626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384626.